EUVIMEDEUVIMED entdecken
Crossref

Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma

Xuechun Wang, Liu Liu, Jing Tian, Zhe Kong, Fei Lv, Jie Yan, Songyan Li, Zilin Ma, Dianhao Guo, Yuelan Wang, Changping Gu, Guiqiang Zhang iD

ACS Nano · 2026

DOI: 10.1021/acsnano.5c21154 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Xuechun Wang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117, C…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Immunotherapy, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, the Large-scale Instrument and Equipment Open Sharing Foundation of Medical Science and Technology Innovation Center, Shandong First Medical University & Shand….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAdenocarcinoma of LungImmunotherapyNanoparticlesPhotosensitizing AgentsCell Cycle ProteinsAntineoplastic AgentsTranscription FactorsAdenosine A2 Receptor AntagonistsHumansAnimalsProteolysis Targeting ChimeraMiceBromodomain Containing ProteinsProteolysisPhotochemotherapyCell Line, TumorTumor MicroenvironmentReceptor, Adenosine A2AFemale

Stichwörter der Autor:innen

BRD4PROTACadenosine 2A receptorimmunosuppressive tumor microenvironmentprogrammed cell death protein ligand 1

Substanzen

Proteolysis Targeting ChimeraBromodomain Containing ProteinsPhotosensitizing AgentsCell Cycle ProteinsAntineoplastic AgentsBRD4 protein, humanTranscription FactorsAdenosine A2 Receptor AntagonistsReceptor, Adenosine A2A

Autor:innen und Institutionen

  • Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.
  • Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, China.
  • Department of Biochemistry and Molecular Biology, School of Clinical and Basic Medical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117, China.

ORCID-Profile: Guiqiang Zhang

Förderung

  • Natural Science Foundation of Shandong Province
  • the Large-scale Instrument and Equipment Open Sharing Foundation of Medical Science and Technology Innovation Center, Shandong First Medical University & Shand…

Zitieren

APA

Wang, X., Liu, L., Tian, J., Kong, Z., Lv, F., Yan, J., Li, S., Ma, Z., Guo, D., Wang, Y., Gu, C., & Zhang, G. (2026). Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma. ACS Nano. https://doi.org/10.1021/acsnano.5c21154

Vancouver

Wang X, Liu L, Tian J, Kong Z, Lv F, Yan J, et al. Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma. ACS Nano. 2026. doi:10.1021/acsnano.5c21154

BibTeX
@article{Wang2026,
  author = {Wang, Xuechun and Liu, Liu and Tian, Jing and Kong, Zhe and Lv, Fei and Yan, Jie and Li, Songyan and Ma, Zilin and Guo, Dianhao and Wang, Yuelan and Gu, Changping and Zhang, Guiqiang},
  title = {Carrier-Free Nano-Proteolysis Targeting Chimeras Enable Selective Protein Degradation and Enhance Photoimmunometabolic Therapy against Lung Adenocarcinoma},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.5c21154}
}
Kostenlos starten →